Cosmos Health Inc. Appoints Dimitrios Iliopoulos To Its Advisory Board To Advance AI-Powered Drug Discovery And Clinical-Stage Biotechnology Strategy

Cosmos Health Inc., a diversified and vertically integrated global healthcare group, has announced the appointment of Dimitrios Iliopoulos to its Advisory Board. In this role, he will help guide the company’s expanding biotechnology strategy, especially in areas involving AI-powered drug discovery and clinical-stage therapeutic development.

Dr. Iliopoulos is internationally recognized for his work in artificial intelligence, drug discovery, and drug development. He is the Co-Founder and CEO of Athos Therapeutics Inc., a clinical-stage biotechnology company using advanced AI systems to create precision medicines for autoimmune diseases. Under his leadership, Athos developed AthosOmics.AI, a proprietary AI-based drug development platform that led to the discovery of ATH-063, a small-molecule therapy now being tested in a Phase 2 clinical trial for patients with ulcerative colitis.

His academic background includes positions at Harvard Medical School, where he began as an Assistant Professor of Microbiology and Immunology, and later at the UCLA School of Medicine, where he became a tenured Associate Professor of Medicine. During his time at UCLA, he founded and directed the UCLA Center for Systems Biomedicine, supported by funding from the Eli and Edythe Broad Foundation.

Throughout his career, Dr. Iliopoulos has been honored by several prestigious institutions, including the National Institutes of Health, the American Association for Cancer Research, the Sidney Kimmel Foundation, and the Leona and Harry Helmsley Foundation. His scientific contributions include more than 130 peer-reviewed publications, accumulating over 24,000 citations. He has also been listed among the top 2% of scientists worldwide in rankings published by Stanford University.

Dr. Iliopoulos has developed influential AI-enabled approaches that have helped accelerate drug discovery in both oncology and autoimmune diseases. His early work at Harvard demonstrated that metformin, a widely used diabetes medication, also showed anti-cancer potential—work that helped support several cancer clinical trials. At UCLA, his group’s identification of miR-124 as a key anti-inflammatory target for ulcerative colitis contributed to the advancement of clinical programs in inflammatory bowel disease.

Beyond his scientific work, he also holds an MBA and finance credentials from the UCLA Anderson School of Management and the Stanford Graduate School of Business. He is co-author of the widely referenced “Biotechnology Valuation & Investing” (2nd Edition) and developed a real-options financial model for evaluating early-stage biotechnology assets.

In his statement about joining the Advisory Board, Dr. Iliopoulos said he was honored to support Cosmos Health and work with its CEO, Greg Siokas. He described Siokas as a leader who blends strong execution with forward-looking strategy and emphasized his excitement for contributing to the company’s growth in biotechnology and AI-driven drug development.

Greg Siokas, CEO of Cosmos Health, expressed enthusiasm for the appointment, noting that Dr. Iliopoulos brings deep expertise across AI-based drug discovery, translational science, and clinical development. He added that as the company expands its research efforts and evaluates programs in oncology, autoimmune disorders, and other high-value therapeutic areas, Dr. Iliopoulos’ combination of scientific insight and strategic biotech experience will play a critical role in shaping its long-term direction.